Extract
Before the introduction of the vartial thrombo~lastin time
Three members of a Virginia family with a bleeding disorder were found t o have a serum defect in thromboplastin generation similar to the previously reported "Car. factor" deficiency. Sera from three members of the original Car. family did not correct the defect of affected members of the Virginia family. Partial thromboplastin times of Car. deficient individuals and affected members of the Virginia family were normal. Although correction with normal serum is attained i n vitro, the serum defect persisted after infusion of fresh frozen plasma.
Platelet function studies of the Virginia family revealed less than 30% aggregation after the addition of exogenous ADP and disaggregation within 2 min. Evaluation of children with Noonan's syndrome, albinism, and "Portsmouth" syndrome showed coexistent platelet aggregation defects and nonspecific serum defects.
(PTT), the thromboplastin generation test (TGT) was used extensively as a screening test for deficiencies of thromboplastin generation. Of tbe officially recognized plasma coagulation factors, serum defect without plasma defect is produced only by deficiencies of factor IX or X. Various serum defects have been reported in persons with normal levels of these two factors who d o not appear t o have inheritable bleeding disorders (2, 9, 15) . In 1957, Chirico and McElfresh (8) reported a familial abnormality of thromboplastin generation detected in the serum component of the TGT. This defect was tentatively named "Car. factor" after the Caucasian family of Italian extraction in whom it was detected. The inheritance was most consistent with autosomal dominance; affected family members had moderate t o severe bleeding problems.
A Virginia family was found t o have a serum defect consistent with the Car. factor deficiency. It is the purpose of this vaver t o revort extended studies that show the * -nonspecific nature of the Car. factor deficiency. Speculation MATERIALS These studies suggest that the Car. factor is nonspecific; the ADP serum defect may result from the interaction of abnormal cellular elements of the blood during clotting of whole blood
The sodium salt of ADP trihydrate (25) 
METHODS
Platelet aggregation studies were performed by a modification of the method of Born and Cross (5) using a Chronolog aggregometer. Patients had not received any medications for a 2-week period. Blood was anticoagulated with 3.8% sodium citrate in a ratio of 9 parts whole blood t o 1 part anticoagulant in a plastic tube. Platelet-rich plasma (PRP) was obtained by centrifugation at 500 X g for 15 min at room temperature.
The PRP was adjusted to a platelet count of about 300,000/mm3 by dilution with the subjects' platelet-poor plasma (PPP). Aggregation studies were performed a t 37' with 0.36 ml PRP and 0.04 ml aggregating agent. Platelet adhesiveness to glass was determined by the method of Salzman (24) .
Prothrombin time (PT), PTT, platelet counts, fibrinogen level, and factor XI11 screen were performed by methods described previously (6, 7, (19) (20) (21) . Peripheral smears made directly from finger stick were examined for platelet morphology and clumping. Factors VIII, IX, X, and XI1 assays were performed by methods based on PT or PTT (4, 10, 22, 23) . The PTA and Fletcher factor deficiencies were excluded by assays based on celite-exhausted plasma (13) . Prothrombin consumption was tested by the method of Biggs and Macfarlane (4) . Bleeding times were performed by a modification of the Ivy method (1). Platelet factor 3 was determined by the method of Hardisty and Hutton (1 1).
The TGTs were performed by modification of the method of Biggs and Macfarlane (3) . Plasma components were prepared by aluminum hydroxide (28) adsorption of citrated plasma. Whole blood was allowed t o clot for 1 , 2 , and 24 hr in contact with the cellular elements in different glass tubes before separation of the sera. Dilutions of plasma and sera were made in imidazole buffer, pH 7.3, just before use. Recalcification of plasma was performed by the addition of 0.025 ml 1.0 M CaC12 and 0.014 ml 3.8% inosithin t o each milliliter of citrated plasma. Cross-correction studies were performed by the addition of 115 volume of diluted correcting serum to 415 volume of diluted test serum.
Inhibitor activity was tested by incubation a t 37' of undiluted normal serum with undiluted test serum for up to 1 hr. Aliquots were removed at 15, 30, and 60 min and diluted t o be used immediately in a TGT with normal adsorbed plasma. If an inhibitor were present, a serum defect with increased severity would be produced by progressive incubation.
BaS04 adsorbed sera were prepared by mixture of 1 ml normal serum with 100 mg BaS04 for 0.5 hr. Coumadin serum was obtained by the mixture of sera from five patients who had received doses of Coumadin sufficient to reduce their plasma prothrombin activity t o 5% and give a marked serum defect in the TGT. None of these patients was receiving any other medications. Prothrombin complex concentrate (29) was diluted with physiologic saline t o give a factor IX concentration of approximately 1 unit/ml before further dilution with buffer for use in the TGT.
Studies were performed on six members of two generations of the Virginia family ( Fig. 1) . Three of the original Car. family (one generation) were restudied in a more limited fashion.
CASE REPORTS CASE 1 AB, the propositus, is a 15-year-old black male who was seen at the University of Virginia Hospital in 1968 for profuse bleeding following a tooth extraction. Transfusion was not necessary but blood loss was sufficient t o make him dizzy. Past history included multiple visits to the emergency room for severe nosebleeds. In 1969, after the transfusion of 1 0 cc/kg fresh frozen plasma, the left first permanent molar was extracted and six other teeth were restored under general anesthesia. Bleeding was minimal. In 1973, he suffered avulsion of his right tibia1 tubercle. The tubercle was pinned without transfusion or bleeding.
On five occasions, including immediately after fresh frozen plasma infusion, TGTs have shown serum defects ( R K is a 13-year-old black male who is the half-brother of AB. He was circumcised at birth without bleeding. He has a history of frequent severe nosebleeds. In 1969, three teeth were extracted under general anesthesia. No blood product was given and there was no bleeding.
A serum defect was present in the TGT on seven occasions of testing. (Fig. 3) . Bleeding time and PTTs have always been normal. Platelet aggregation curves were similar to those obtained in his half-brother (Fig. 4) . CASE 3 GK is a 35-year-old black woman and the mother of A B and Her platelets respond normally to ADP and norepinephrine but poorly to collagen. The same serum defect in TGT was found. CASE 10 AM is a 5-year-old Caucasian girl with a history of severe bruising since infancy. Her bleeding time is greater than 15 min, requiring pressure dressing for hemostasis. Factor VIII assays are consistently normal. Her platelet factor 3 activity is normal but no aggregation occurs when ADP, collagen, norepinephrine, or thrombin is added to her PRP. Her thromboplastin generation test shows a serum defect with the same characteristics. CASE 11 RK. She has had multiple episodes of metamenorrhagia but MM is an i-year-old Caucasian male from the same has had six term deliveries and one miscarriage without excessive bleeding. She has had frequent nosebleeds and community and with the same surname as case 10. The abnormal hematoma formation after lacerations. families are not aware of being related. His history is milder
Her coagulation studies have shown normal bleeding time, normal PTT, and a serum defect in the TGT on four occasions. As seen in her sons, platelet aggregation to collagen, norepinephrine, and thrombin was normal. No secondary wave of aggregation was seen after exogenous ADP and rapid disaggregation occurred. HS is a 15-year-old Caucasian girl with Noonan's syndrome and pulmonic stenosis. Although her bleeding time and PTT are normal, she has a serum defect in TGT summarized in Table 1 . Her platelets fail to show secondary aggregation with ADP, norepinephrine, or thrombin but respond normally to collagen. She did not bleed excessively during or after open heart surgery. CASE 8 JM is a 12-year-old black male with Noonan's syndrome and pulmonic stenosis. As with HS, his bleeding time and PTT are normal but a serum defect is present in the TGT with characteristics summarized in Table 1 . Not even primary aggregation of platelets is seen with ADP, norepinephrine, collagen, or thrombin. CASE 9 M R is a 9-year-old girl with partial albinism and a history of easy bruising. Her bleeding time is 4 min and PTT is normal. LA is a 5-year-old male with severe classic hemophilia (<I% AHF). Family history includes documented classic hemophilia in maternal brothers and nephews. Both parents and three sisters are asymptomatic and have normal factor VIII levels and bleeding times. A bleeding time obtained on LA at the time of initial diagnosis was normal. The TGT revealed typical plasma defect seen in classic hemophilia. Platelet aggregation t o ADP, collagen, norepinephrine, and thrombin were normal.
During an episode of acute hemarthrosis, factor VIII concentrates were given and the AHF level assayed at 55% of normal. Because of pain, aspirin was administered. Eight hours later, the hemarthrosis was unimproved and nosebleeding began. AHF was assayed at 40% of normal; bleeding time was >15 min. Platelets showed impaired aggregation t o ADP, collagen, norepinephrine, and thrombin. A TGT showed a serum defect only. Re-evaluation 2 weeks later showed a normal bleeding time, normal platelet aggregation, and n o serum defect on TGT.
CASES 13-22
Ten normal adult male volunteers were studied before and 2 hr after ingestion of 10 grains aspirin. The results are summarized in Table 1 . The following coagulation studies were normal in all affected members of the Virginia and Car. families: PT, PTT, platelet count, platelet morphology, fibrinogen, factors 11, V, VII-X, XI, XII, Fletcher factor, prothrombin consumption, platelet factor 3, bleeding time, Rumple-Leed test, clot retraction, and platelet adhesiveness.
THROMBOPLASTIN GENERATION CROSS-CORRECTION STUDIES
All clinically affected members of both families had serum defects of the TGT when the "serum" was formed by the clotting of whole blood. Recalcification of citrated plasma with clot retraction by inosithin did not yield consistent results on the Virginia family ( Table 2) . Although a serum defect was occcasionally found this was, on other occasions, absent. "Serum" formed in this manner from three members of the Car. family gave normal results in the TGT.
The addition of 115 normal serum by volume was adequate t o correct the defect in both families. Addition of 115 t o 415 volume serum from any of the three Car. family members did not correct AB, GK, or R K (Fig. 3) .
Addition of 115 t o 415 volume BaS04-absorbed serum did not correct any of the affected individuals, but all were corrected by prothrombin complex concentrate or Coumadin serum (Fig. 2) .
Although the defect was present in serum incubated for only 1 hr in contact with its clot, the defect was more marked in both the Car. and Virginia families after prolonged incubation (Fig. 5) .
Inhibitory activity was not demonstrated for either "Car.-deficient" serum or serum from affected members of the Virginia family. Incubation at 37' of these sera with normal sera for periods up t o an hour did not produce any abnormalities.
The addition of from 0.02 t o 0.04 units of thrombin t o the reaction mixture corrected the defect of both the Virginia and Car. families (Fig. 6) . Addition of 0.04 units thrombin t o a reaction mixture containing serum from a patient with less than 1% factor IX was not corrective.
Normal serum heated t o 60' for 3 rnin was not capable of correcting the defect of the Virginia or Car. families, but was itself corrected by the addition of 0.02 units thrombin. (GK, R K , and A B ) , aggregation t o norepinephrine, collagen, N.S.
-N.S. and thrombin were normal. When 1-4 yM ADP were used as the aggregating agent, there was no secondary wave of aggregation and disaggregation was rapid, even at 4 y M ADP (Fig. 4) .
HEMOGLOBIN ELECTROPHORESIS
All members of the Virginia family and Car. family have hemoglobin A with normal levels of A2 and F. None have hemolytic anemias or reticulocytosis.
DISCUSSION
The coagulation defect in all these patients is characterized by defective serum components in the TGT in the face of a normal PTT. The lack of cross-correction by Virginia and Car. sera suggest that the defective component is identical. The normal PTTs, loss of the defect when recalcified plasma is substituted for true serum, and failure of plasma transfusion t o correct the TGT suggest that this is an artifact of serum preparation rather than deficiency of a new coagulation factor in the intrinsic pathway.
Serum defects in TGT have been described in association with hemoglobinopathies (2, IS), presumably from interaction of the abnormal red cell and the forming serum. These defects are more pronounced on prolonged incubation. Hemoglobin electrophoresis is normal in both families described.
In addition t o the Car. factor and hemoglobinopathy patients, Connor et al. (9) reported a series of patients with "labile serum factor." Table 2 summarizes a comparison of the reported serum defects. Except for minor differences, it is likely that these reports probably involve the same defect. Both Henstell et al. (15) and Connor e t al. (9) reported correction of the defect by the addition of dilute thrombin t o the reaction mixture and failure of heated (thrombin-inacti- Platelet aggregation studies in the Virginia family revealed a qualitative platelet defect. Similar studies were not performed on the Car. family so that a platelet defect has not been confirmed. After our identification of the platelet defect in patients with "Car. defects," we restudied patients in whom we had previously identified either a nonspecific serum defect or platelet aggregation defect. Identification of concurrent platelet and TGT defects in these additional patients suggests that the Car. factor deficiency is a nonspecific defect. Rather than representing the deficiency of a plasma coagulation factor, it represents the removal of, or failure t o generate thrombin in the presence of an abnormal cellular element of the blood, either red blood cell or platelet.
The platelet defect in the Virginia family bears some resemblance to the "platelet release defects" (12, 18) ; normal platelet factor 3, abnormal aggregation t o exogenous ADP, and normal bleeding time in some individuals (17) . In our series normal bleeding times in association with previously described qualitative platelet defects (14, 16) were seen with Noonan's syndrome and albinism. Although patients with significant clinical bleeding problems usually have prolonged bleeding times, this time-honored screening test may not be adequate t o detect all cases of qualitative platelet dysfunction.
The presence of the same serum defect in TGTs of patients with a variety of qualitative platelet defects including aspirin-induced release defect emphasizes the nonspecificity of the serum defect that n o longer merits the name of "Car.
factor deficiency ."
CAR. FACTOR DEFICIENCY 189 SUMMARY The previously described "Car. factor" deficiency appears to be a nonspecific removal of thrombin from serum during the interaction of abnormal cellular elements of the blood during clotting of whole, blood in glass.
In the new cases described, bleeding time and PTT were inadequate to identify patients with significant bleeding problems. In patients with histories suggestive of a significant bleeding disorder but with normal screening studies, further testing may be required to clarify the problem.
